Is Medicamen Organ. overvalued or undervalued?

As of 13 October 2025, the valuation grade for Medicamen Organ. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 12.51, an EV to EBITDA of 8.96, and a ROCE of 12.71%.
In comparison to its peers, Medicamen Organ. stands out with a PE ratio that is significantly lower than Sun Pharma's 34.9 and Divi's Lab's 75.45, both of which are classified as expensive. Additionally, the PEG ratio for Medicamen is at 0.00, indicating potential undervaluation relative to growth expectations. While the stock has underperformed the Sensex over the past year, with a return of -40.46% compared to the Sensex's 1.05%, the current valuation suggests that it may present a more attractive investment opportunity within the pharmaceuticals sector.